Pemetrexed Injection, Solution
Product Images NDC 0781-3519

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 0781-3519). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical-structure (Pemetrexed 01)

Chemical structure of pemetrexed disodium hydrate showing the molecular arrangement including carboxylate groups, amide linkage, aromatic ring, and hydrate component (2.5 H2O).*

FDA Label Image

Figure-1 (Pemetrexed 02)

A Kaplan-Meier survival curve illustrating overall survival (%) over time in months for two treatment arms in a clinical study. The solid line represents A+P+C (pemetrexed, pembrolizumab, and platinum chemotherapy) and the dashed line represents A+C (pemetrexed, platinum chemotherapy, and placebo). The graph includes a table of numbers at risk for each group at various time points up to 21 months.*

FDA Label Image

Figure2 (Pemetrexed 03)

A survival probability plot comparing Pemetrexed plus Cisplatin (AC) versus Gemcitabine plus Cisplatin (GC) over 30 months. The x-axis shows survival time in months, and the y-axis shows survival probability. The graph includes patient numbers at risk for both treatment groups at various time points.*

FDA Label Image

Figure3 (Pemetrexed 04)

A Kaplan-Meier survival probability plot comparing two chemotherapy regimens: Pemetrexed plus Cisplatin (AC) represented with a solid black line, and Gemcitabine plus Cisplatin (GC) with a dashed gray line. The x-axis shows survival time in months up to 30, and the y-axis shows survival probability from 0 to 1. Below the graph, the number of patients at risk at selected time points is listed for each regimen.*

FDA Label Image

Figure4 (Pemetrexed 05)

A Kaplan-Meier survival curve chart comparing survival probability over time in months for two chemotherapy regimens: Pemetrexed plus Cisplatin (AC) shown with a solid black line, and Gemcitabine plus Cisplatin (GC) shown with a dashed gray line. The chart includes a table listing the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure5 (Pemetrexed 06)

A Kaplan-Meier survival curve comparing survival probability over time (months) between Pemetrexed injection and placebo groups. The solid line represents Pemetrexed, and the dashed line represents placebo. Below the graph, a table shows the number of patients at risk for each group at various time points up to 42 months.*

FDA Label Image

Figure6 (Pemetrexed 07)

A Kaplan-Meier survival curve comparing survival probability over time (months) between patients treated with Pemetrexed and those given placebo. The chart includes survival probability on the y-axis and survival time in months on the x-axis, with Pemetrexed represented by a solid line showing higher survival probability than the dashed placebo line. Below the graph, a table lists the number of patients at risk at various time points for each group.*

FDA Label Image

Figure7 (Pemetrexed 08)

A Kaplan-Meier survival curve comparing survival probability over time in months for Pemetrexed injection versus placebo. The graph shows two lines representing survival probability for patients treated with Pemetrexed and placebo, with survival decreasing over approximately 42 months. A table below the graph lists the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure8 (Pemetrexed 09)

A survival probability curve comparing Pemetrexed injection solution to placebo over a 36-month period. The graph plots survival probability on the y-axis against survival time in months on the x-axis, showing two lines for Pemetrexed and placebo. Below the graph is a table listing the number of patients at risk at specific time points for each group.*

FDA Label Image

Figure9 (Pemetrexed 10)

A survival curve chart comparing survival probability over time (in months) between two treatment groups: Pemetrexed plus Cisplatin versus Cisplatin alone. The chart includes a survival probability y-axis ranging from 0.0 to 1.0 and a time x-axis from 0 to 30 months. The curve for Pemetrexed plus Cisplatin is shown with a solid line, and Cisplatin alone with a dashed line. Below the graph, a table lists the number of patients at risk for each group at various time points.*

FDA Label Image

100mg-carton (Pemetrexed 11)

Packaging label for Pemetrexed Injection 100 mg/4 mL (25 mg/mL) solution for intravenous infusion, single-dose vial. The label shows it is a cytotoxic agent for intravenous infusion only after dilution, manufactured by Sandoz Inc. It includes storage instructions, active ingredient details per mL, and dilution guidance with sodium chloride injection. The label also states to discard unused portions and includes barcodes and regulatory information.*

FDA Label Image

500mg-carton (Pemetrexed 12)

Packaging label for Pemetrexed Injection 500 mg/20 mL (25 mg/mL) intravenous solution, a cytotoxic agent. The single-dose vial is for intravenous infusion only after dilution, with instructions to discard unused portions. Label includes storage instructions, active ingredient quantities, dilution recommendations, and manufacturer information for Sandoz Inc.*

FDA Label Image

1000mg-carton (Pemetrexed 13)

Packaging label for Pemetrexed Injection 1,000 mg/40 mL (25 mg/mL) solution for injection by Sandoz Inc. The label indicates it is a sterile, single-dose vial for intravenous infusion only after dilution. It is marked as a cytotoxic agent with storage instructions of 25°C with allowable excursions, and includes dosage and dilution information on the carton.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.